Derivation of the minimal magnitude of the Critical Effect Size for continuous toxicological parameters from within-animal variation in control group data

Burtis, 1999 Couto, 2004 Crump, 1984, A new method for determining allowable daily intakes, Fundam. Appl. Toxicol., 4, 854, 10.1016/0272-0590(84)90107-6 2003 Dekkers, 2001, Critical effect sizes in toxicological risk assessment: a comprehensive and critical evaluation, Environ. Toxicol. Pharmacol., 10, 33, 10.1016/S1382-6689(01)00068-0 Dekkers, 2006, Within-animal variation as an indication of the minimal magnitude of the critical effect size for continuous toxicological parameters applicable in the benchmark dose approach, Risk Anal., 26, 867, 10.1111/j.1539-6924.2006.00784.x Endres, 1999, Mineral and bone metabolism, 1395 Fiorenza, 1996, Serum cholesterol levels in patients with cancer. Relationship with nutritional status, Int. J. Clin. Lab. Res., 26, 37, 10.1007/BF02644772 Guyton, A.C., 1991a. Insulin, glucagon and diabetes. In: Textbook of Medical Physiology, eighth ed. W.B. Saunders Company, Philadelphia, USA (Chapter 78), pp. 855–867. Guyton, A.C., 1991b. Parathyroid hormone, calcitonin, calcium and phosphate metabolism, vitamin D, bone and teeth. In: Textbook of Medical Physiology, eighth ed. W.B. Saunders Company, Philadelphia, USA (Chapter 79), pp. 868–884. Guyton, A.C., 1991c. Resistance of the body to infection: immunity and allergy. In: Textbook of Medical Physiology, eighth ed. W.B. Saunders Company, Philadelphia, USA (Chapter 34), pp. 374–384. Guyton, 1991 Guyton, A.C., 1991e. The microcirculation and the lymphatic system. In: Textbook of Medical Physiology, eighth ed. W.B. Saunders Company, Philadelphia, USA (Chapter 16), pp. 170–184. Guyton, A.C., 1991f. Hemostasis and blood coagulation. In: Textbook of Medical Physiology, eighth ed. W.B. Saunders Company, Philadelphia, USA (Chapter 36), pp. 390–399. Huxley, 2002, Cholesterol, coronary heart disease and stroke: a review of published evidence from observational studies and randomized controlled trials, Semin. Vasc. Med., 2, 315, 10.1055/s-2002-35402 Johnson, 1999, Proteins, 477 Kritchevsky, 1992, Serum cholesterol and cancer risk: an epidemiologic perspective, Annu. Rev. Nutr., 12, 391, 10.1146/annurev.nu.12.070192.002135 Moss, 1999, Clinical enzymology, 617 Newman, 1999, Renal function and nitrogen metabolites, 1204 Rifai, 1999, Lipids, lipoproteins and apolipoproteins, 809 Slob, 2002, Dose–response modeling of continuous endpoints, Toxicol. Sci., 66, 298, 10.1093/toxsci/66.2.298 Slob, 1998, A probabilistic approach for deriving acceptable human intake limits and human health risks from toxicological studies: general framework, Risk Anal., 18, 787, 10.1111/j.1539-6924.1998.tb01121.x Tolman, 1999, Liver function, 1125 USEPA, 1995. The Use of the Benchmark Dose Approach in Health Risk Assessment. Report No. EPA/630/R-94/007. US Environmental Protection Agency, Washington.